Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer

Summary

Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques. SABR is non-invasive and delivered on an outpatient basis. The purpose of this study is to compare the effect of SABR, relative to standard of care (SOC) alone, on overall survival, progression-free survival, toxicity, and quality of life. An integrated economic evaluation will determine the cost per quality of life year gained using SABR (vs. SOC) and a translational component will enable identification of predictive/prognostic biomarkers of the oligometastatic state.

Conditions

• Metastatic Tumors

Interventions

RADIATION

palliative radiotherapy

Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Patients in this arm should not receive stereotactic doses or radiotherapy boosts. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.

RADIATION

Stereotactic ablative radiotherapy

Lung: Tumors 5 cm or less surrounded by lung parenchyma 48 Gy/4#, or 54 Gy/3#, daily or every second day Within 2 cm of mediastinum or brachial plexus 60 Gy/8#, daily Bone: Any bone 35 Gy/5#, or 24 Gy/2#, daily Brain: Stereotactic lesions (no whole brain RT) \<2cm 20-24 Gy/1#, once 2-3 cm 18 Gy/1#, once Metastases only: 35Gy/5# to PTV, daily Whole brain + Mets: 35Gy to metastases, daily 20 Gy whole brain, daily Liver: 54 Gy/3#, every second day Adrenal/Pancreas: 40 Gy/5# / 35Gy/7#, daily Lymph Node: 40 Gy/5#, daily

Sponsors & Collaborators

• London Regional Cancer Program, Canada

  collaborator OTHER

• The Alfred

  collaborator OTHER

• Beacon Hospital, Ireland

  collaborator UNKNOWN

• Cancer Trials Ireland

  collaborator NETWORK

• Cancer Research UK Edinburgh Centre

  collaborator UNKNOWN

• Bon Secours Cork Cancer Centre

  collaborator UNKNOWN

• UPMC Hillman Cancer Centre

  collaborator UNKNOWN

• Beatson West of Scotland Cancer Centre

  collaborator UNKNOWN

• Tom Baker Cancer Centre

  collaborator OTHER

• Walker Family Cancer Centre

  collaborator UNKNOWN

• Riverina Cancer Care Centre

  collaborator UNKNOWN

• Aberdeen Royal Infirmary

  collaborator OTHER

• British Columbia Cancer Agency

  lead OTHER

Principal Investigators

• Robert A Olson, MD, MSc, FRCPC · BC Cancer Prince George

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-11-01

Primary Completion

2030-11-24

Completion

2030-12-31

Countries

• Australia
• Canada
• Ireland
• United Kingdom

Study Locations